Chain Drug Review - Battle over Clarinex switch. (Marketplace: Focus).
WASHINGTON–The National Consumers League (NCL) wants the Food and Drug Administration to keep Clarinex as a prescription-only product. The medication reached the market in January.
Earlier this year WellPoint Health Networks Inc. filed a petition with the regulatory agency to gain approval for an over-the-counter version of the Schering-Plough Corp. allergy product.
Related Results
WALL STREET CHOICE: SCHERING-PLOUGH SHOWS PROMISE
Marlborough, Mass., Firm’s Allergy Drug Is Turned Away by FDA.
Manufacturing Problems Cast Pall on Schering-Plough Earnings.(Statistical Dat…
Tab for Allergy Pills Likely to Rise.
New Jersey Insurers’ Changed Policy on Allergy Drugs Presents New Irritant.
“The consequence of this forced O-T-C shift along with other NSAs that WellPoint has petitioned on would be to eliminate the insurance coverage for the entire class of nonsedating antihistamines, reduce …
Read the rest of this article with a Free Trial at HighBeam Research.
